Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
← catalyst calendarSponsored by Atea Pharmaceuticals, Inc. (industry) · AVIR — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-09 | actual | When the study began enrolling |
| Primary completion | 2025-06-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-28 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer Study
Interventions
- Drug: Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting — also filed as BEM/RZR FDC, BEM (AT-527)/RZR (AT-038)
- Drug: Treatment B-Omeprazole 20 mg dose administered fasting — also filed as Omeprazole, Prilosec®
- Drug: Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting — also filed as BEM/RZR and Omeprazole, BEM (AT-527)/RZR (AT-038) and Prilosec®
- Drug: Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole — also filed as BEM/RZR and Omeprazole, BEM (AT-527)/RZR (AT-038) and Prilosec®
- Drug: Treatment E-Omeprazole 40 mg administered fasting — also filed as Omeprazole, Prilosec®
- Drug: Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole — also filed as BEM/RZR and Omeprazole, BEM (AT-527)/RZR (AT-038) and Prilosec®
Primary outcomes
what the primary-completion date above is the date OFPK of BEM/RZR
measured Day 1, 8, 13, 18
PK of BEM/RZR
measured Day 1, 7, 8, 13, 18
PK of Omeprazole
measured Day 7, 8
PK of Omeprazole
measured Day 7, 8
Permalink · AVIR's whole pipeline · Catalyst calendar · Every registered study · What changed